<DOC>
	<DOCNO>NCT00038662</DOCNO>
	<brief_summary>The purpose phase II , randomize , double-blind placebo control , multi-center study evaluate safety efficacy 10 mg atrasentan hormone naive subject measure rate rise PSA ( primary objective ) .</brief_summary>
	<brief_title>Safety Efficacy Atrasentan Men With Hormone Naive Prostate Cancer Exhibiting Early Signs Biochemical Failure</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<mesh_term>Atrasentan</mesh_term>
	<criteria>prostate adenocarcinoma , radical prostatectomy , PSA 0.4 5 ng/mL , PSADT &lt; 1 year previous hormonal therapy , salvage therapy pelvis within 3 month prior randomization</criteria>
	<gender>Male</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2006</verification_date>
</DOC>